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Objective: to evaluate the use of percutaneous transluminal renal angioplasty (PTRA) in the treatment of renal vascular hypertension.
Design: sequential prospective PTRA treatment of severe arterial hypertension, screening by the captopril test, confirmed by renal
arteriography, and the result evaluated by post-PTRA arteriography, blood pressure measurement and renal function. Site: Vascular
Surgery, angioradiology sector, and Nephrology outpatients department of the Federal University of Sao Paulo - Paulista School of
Medicine, Sao Paulo, Brazil, a tertiary health-care institution. Participants: PTRA was employed on 32 patients screened by clinical
examination, captopril test and renal arteriography. Evaluation: PTRA results were evaluated by the criteria of the Cooperative Study
of Renovascular Hypertension. Results: after PTRA the completion arteriography showed no renal stenosis in 24 patients (75%),
residual stenosis (20-50%) in 3 (9.4%) and no change in 5 (15.6%). The blood pressure results were: 3 patients (9.4%) were cured, 24
(75%) improved and 5 (15.6%) were unchanged. We observed normal renal function before and after PTRA in 25 patients (78%);
altered pre- and improved post-PTRA in 2 (6.3%); post-PTRA remained unaltered in 2 (6.3%); and altered pre- and worsened post-
PTRA in 3 (9.4%). Recurrence of stenosis occurred in one patient after 8 months. Conclusions: PTRA is a convenient procedure,
relatively safe and an effective complementary method of medical therapy for controlling renovascular hypertension.
UNITERMS: Renovascular hypertension. Transluminal angioplasty. Renal artery stenosis. Atherosclerosis. Fibromuscular dysplasia.
INTRODUCTION
The use of percutaneous transluminal angioplastyfor the treatment of renal artery stenosis (PTRA)was first reported by Gruntzig et al (I) in 1978,
and since then the results of PTRA have been reported
by several centers (2-10).
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Acquired experience has reduced the complications
rate and primary success has reached nearly 900/0(2-13) with
good results above 70% in longer follow-ups (14-20). The
treatment decision is taken by a multidisciplinary team,
PTRA being the first choice except in cases of anticipated
technical difficulties, treating one renal lesion at time in
cases of bilateral lesion. PTRA has a low incidence of
technical failure and renal loss, being the preferred route
for inguinal. catheterism. Balloon-catheter insufflation at
the stenosis site breaks the intimal layer, the atherosclerotic
plaque and the medial layer, dilating the renal artery (21,22).
Complications have been reduced and primary successes
increased with greater experience and technological
advance, using digital subtraction angiography, reduced
quantities of injected contrast, adequate hydration and
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better materials (23). Good results have been observed in
children (1~J), transplanted kidneys (24\ segmental renal
branches (25), ostial lesions (26,27) and even in short segmental
obstructions (28). PTRA is considered a long-term effective
treatment for preventing renal function impairment and
controlling blood pressure (19,24,25).
The good results observed in the medical literature
have led us to use this procedure and the aim of this article
is to summarize our experience. with PTRA in the
treatment of renovascular hypertension.
PATIENTS AND METHODS
Out of a total of 2,554 angiograms performed during
a five year period, 137 patients (5.6%) with arterial
hypertension underwent screening renal arteriography.
Percutaneous transluminal renal angioplasty (PTRA) was
performed on 32 patients with renovascular hypertension
Table 1
Patient distribution according to age group
diagnosed by the clinical examination, renal function tests,
captopril test and renal angiography.
The mean age was 36 years (range 1 to 70) (table
1), and the cause of renal arterial stenosis is summarized
in table 2.
The technique used for renal angioplasty did not
differ from the classic techniques reported in the literature
(29-32). Acetylsalicylic acid 500 mg/day was prescribed for
six months after the procedure.
The results were evaluated in accordance with the
criteria of the Cooperative Study of Renovascular
Hypertension (33):
1 - The technical results before and after PTRA were
quantified as: without stenosis, having residual
stenosis (20-50%), and unchanged.
2 -The blood pressure results were classified as
cured (without antihypertensive drugs),
improved (controlled with decreased doses of
antihypertensive drugs), and unchanged.
3 - the renal function results before and after PTRA
were classified by the creatinine dosage needed.
4 - the complications of the procedure and recurrence
of the hypertension.
RESULTS
Table 2
Etiology of renal artery stenosis
Age (years) Patients
01 - 10 1
11 - 20 0
21 - 30 8
31 - 40 7
41 - 50 8
51 - 60 6
61 - 70 2
Total 32
Etiology
Fibromuscular Dysplasia
Atherosclerosis
Takayasu Disease
Renal Transplant
Total
Patients
16
12
2
2
32
1 - The technical results of PTRA were shown by
the completion arteriography: renal artery without
stenosis in 24 patients (75%), residual stenosis
in 3 (9.4%), and unchanged in 5 (15.6%).
2 -The blood pressure results ranged from one
month to five years (mean period of 16 months),
. showing: three patients (9.4%) had diastolic
blood pressure under 90 mmHg without
medication; in 24 (75%) diastolic pressure under
109 mmHg was achieved with decreased doses
of antihypertensive drugs taken; and in 5
(15.6%) the pressure was unchanged.
3 - Renal function results: we observed normal renal
function before and after PTRA in 25 patients
(78%); impaired before and improved after PTRA
in 2 (6.3%); remaining impaired in post-PTRA
in 2 (6.3%); and impaired before and worsened
after PTRA in 3 (9.4%).
4 - Complications occurred in 10 patients and are
listed in table 3. In 5 (15.6%), PTRA failed to
achieve dilation of the stenotic lesion: two
underwent ~urgical renal revascularization and
one was submitted to a new PTRA successfully.
The others were treated medically.
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DISCUSSION
Recurrence of stenosis occurred in one patient after
8 months, which was treated with another successful
PTRA after the termination of this work.
Table 3
Complications in 10 out of 32 patients treated with
percutaneous transluminal angioplasty
Renal function impairment and the progression of
renovascular disease has been associated with the clinical
treatment of renovascular hypertension. PTRA and
surgical treatment result in better control of arterial
hypertension with lesser occurrence of cardiovascular
events and mortality, preserving renal function (lR,33,34).
The use of PTRA in the treatment of renovascular
hypertension has lower operative risk and the results are
comparable to surgical treatment (R,IR).
To evaluate the results of PTRA the criteria of the
Cooperative Study of Renovascular Hypertension were
used (33). The technical results of PTRA depend upon the
stenosis characteristics (29), chiefly the etiology, our best
results being the treatment of fibromuscular hyperplasia
which was similar to other authors (14,15,19,25,31,35-38). These
good results, ranging from 89 to 100%, may be attributed
to younger age groups and lesser effects of hypertension
on contralateral kidney and systemic vessels (21). Recently,
with a minor procedural risk, a cure rate of less than 300/0
has been obtained in the atherosclerotic group, which
should be compared with rates greater than 50% in the
fibromuscular dysplasia group (18). No significant
difference has been found between ostial and non-ostial
PTRA treatment results of renal lesions (20,26,27). These
findings are different from some works relating ostial
dilating difficulties compared with non-ostial lesions
(15,29,39), because ostial plaque is generally an extension of
aortic plaque.
The PTRA cure rate is low, ranging from 60/0(40) to
25%(4,15), and the best results have been obtained in
fibromuscular dysplasia (25). In our experience the cure rate
was 9.4%. The hypertension control with decreased doses
of medication was a real benefit, as obtained in 750/0 of
our patients treated with PTRA and in accordance with
other authors (21) (table 4).
The PTRA complication rate ranged from 7.2%(34)
to 46.2%(16\ with local complications being the most
frequent. We observed PTRA complications in 10 patients
(table 3). However, the lack of comparability between
patients in different series and the problem of definition
of a "complication" leaves the discussion of this issue
outside of the scope of this paper.
In 5 cases (15.6%) it was not possible to dilate the
renal stenosis, which is comparable to other authors'
reports relating technically unsuccessful dilation ranging
from zero to 15%(l1-13,IR-21,23-27). In these cases surgical
treatment or a new PTRA should be performed. In one of
our patients, changing the femoral catheterization method
2
2
2
2
1
1
10
PatientsComplications
Total
Nausea
Local Hematoma
Renal Artery Dissection
Renal Art. Perforation + Nausea .
Renal Art. Perforation
Hematoma + Arterial Hypertension
Table 4
Percutaneous transluminal angioplasty results in patients with atheromatous
or fibromuscular dysplasia lesions colle~ted from several authors
Lesion Type Cured Improved Unchanged Total
(%) (%) (%) (N)
Atheromatous 19 51 30 360
Fibromuscular Dysplasia 46 45 9 163
Modified from Libertino & Beckmann, 1994. (21)
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to the axillar route made the catheteriiation and dilation
of the renal artery successful.
In the literature, a recurrence rate of 5 to 8% has
been reported (9,15,20,41). Generally, most recurrences take
place within the first year (l7). Our patient with recurrence
of renal stenosis 8 months after PTRA was successfully
submitted to redilation after the end of this study. The use
of PTRA and "stents" has been recommended for
diminishing the recurrence of renal stenosis (42,43), although
these devices are at present expensive and are not available
in the public hospital where we work.
In conclusion, PTRA is a relatively safe and
convenient procedure and an effective complementary
method of medical therapy for controlling hypertension.
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